186 related articles for article (PubMed ID: 11699828)
1. Development of a lyophilized parenteral pharmaceutical formulation of the investigational polypeptide marine anticancer agent kahalalide F.
Nuijen B; Bouma M; Talsma H; Manada C; Jimeno JM; Lopez-Lazaro L; Bult A; Beijnen JH
Drug Dev Ind Pharm; 2001 Sep; 27(8):767-80. PubMed ID: 11699828
[TBL] [Abstract][Full Text] [Related]
2. Compatibility and stability of the investigational polypeptide marine anticancer agent kahalalide F in infusion devices.
Nuijen B; Bouma M; Manada C; Jimeno JM; Lazaro LL; Bult A; Beijnen JH
Invest New Drugs; 2001; 19(4):273-81. PubMed ID: 11561686
[TBL] [Abstract][Full Text] [Related]
3. In vitro hemolysis and buffer capacity studies with the novel marine anticancer agent kahalalide F and its reconstitution vehicle cremophor EL/ethanol.
Nuijen B; Bouma M; Manada C; Jimeno JM; Bult A; Beijnen JH
PDA J Pharm Sci Technol; 2001; 55(4):223-9. PubMed ID: 11505554
[TBL] [Abstract][Full Text] [Related]
4. Pharmaceutical development of a parenteral lyophilized formulation of the novel antitumor agent aplidine.
Nuijen B; Bouma M; Henrar RE; Floriano P; Jimeno JM; Talsma H; Kettenes-van den Bosch JJ; Heck AJ; Bult A; Beijnen JH
PDA J Pharm Sci Technol; 2000; 54(3):193-208. PubMed ID: 10927911
[TBL] [Abstract][Full Text] [Related]
5. Pharmaceutical development, quality control, stability and compatibility of a parenteral lyophilized formulation of the investigational polymer-conjugated platinum antineoplastic agent AP5346.
Van der Schoot SC; Nuijen B; Sood P; Thurmond KB; Stewart DR; Rice JR; Beijnen JH
Pharmazie; 2006 Oct; 61(10):835-44. PubMed ID: 17069422
[TBL] [Abstract][Full Text] [Related]
6. Moisture sorption behavior of selected bulking agents used in lyophilized products.
Fakes MG; Dali MV; Haby TA; Morris KR; Varia SA; Serajuddin AT
PDA J Pharm Sci Technol; 2000; 54(2):144-9. PubMed ID: 10822985
[TBL] [Abstract][Full Text] [Related]
7. Compatibility and stability of aplidine, a novel marine-derived depsipeptide antitumor agent, in infusion devices, and its hemolytic and precipitation potential upon i.v. administration.
Nuijen B; Bouma M; Henrar RE; Manada C; Bult A; Beijnen JH
Anticancer Drugs; 1999 Nov; 10(10):879-87. PubMed ID: 10630355
[TBL] [Abstract][Full Text] [Related]
8. Chemical and enzymatic stability of a cyclic depsipeptide, the novel, marine-derived, anti-cancer agent kahalalide F.
Sparidans RW; Stokvis E; Jimeno JM; López-Lázaro L; Schellens JH; Beijnen JH
Anticancer Drugs; 2001 Aug; 12(7):575-82. PubMed ID: 11487713
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors.
Pardo B; Paz-Ares L; Tabernero J; Ciruelos E; García M; Salazar R; López A; Blanco M; Nieto A; Jimeno J; Izquierdo MA; Trigo JM
Clin Cancer Res; 2008 Feb; 14(4):1116-23. PubMed ID: 18281545
[TBL] [Abstract][Full Text] [Related]
10. Pharmaceutical development of a parenteral lyophilized formulation of the novel indoloquinone antitumor agent EO9.
Jonkman-de Vries JD; Talsma H; Henrar RE; Kettenes-van den Bosch JJ; Bult A; Beijnen JH
Cancer Chemother Pharmacol; 1994; 34(5):416-22. PubMed ID: 8070009
[TBL] [Abstract][Full Text] [Related]
11. Formulation Screening and Freeze-Drying Process Optimization of Ginkgolide B Lyophilized Powder for Injection.
Liu D; Galvanin F; Yu Y
AAPS PharmSciTech; 2018 Feb; 19(2):541-550. PubMed ID: 28849380
[TBL] [Abstract][Full Text] [Related]
12. A new mechanism for decreasing aggregation of recombinant human interferon-gamma by a surfactant: slowed dissolution of lyophilized formulations in a solution containing 0.03% polysorbate 20.
Webb SD; Cleland JL; Carpenter JF; Randolph TW
J Pharm Sci; 2002 Feb; 91(2):543-58. PubMed ID: 11835212
[TBL] [Abstract][Full Text] [Related]
13. Stability characterization and appearance of particulates in a lyophilized formulation of a model peptide hormone-human secretin.
Srinivasan C; Siddiqui A; Korang-Yeboah M; Khan MA
Int J Pharm; 2015 Mar; 481(1-2):104-13. PubMed ID: 25636302
[TBL] [Abstract][Full Text] [Related]
14. Stabilization of rasburicase and physico-chemical characterization of the resulting injectable formulation.
Bayol A; Breul T; Dupin P; Menegotto J; Aleman C; Duplaa H; Faure P; Bonnet MC; Bauer M
Drug Dev Ind Pharm; 2004 Sep; 30(8):877-89. PubMed ID: 15521333
[TBL] [Abstract][Full Text] [Related]
15. Pharmaceutical development of a parenteral lyophilized formulation of the investigational polymer-conjugated platinum anticancer agent AP 5280.
Bouma M; Nuijen B; Harms R; Rice JR; Nowotnik DP; Stewart DR; Jansen BA; van Zutphen S; Reedijk J; van Steenbergen MJ; Talsma H; Bult A; Beijnen JH
Drug Dev Ind Pharm; 2003 Oct; 29(9):981-95. PubMed ID: 14606662
[TBL] [Abstract][Full Text] [Related]
16. Pharmaceutical development of a parenteral lyophilized formulation of the investigational antitumor neuropeptide antagonist [Arg6, D-Trp7,9, MePhe8]-Substance P [6-11].
Jonkman-de Vries JD; Rosing H; Talsma H; Henrar RE; Kettenes-van den Bosch JJ; Bult A; Beijnen JH
Invest New Drugs; 1998; 16(2):99-111. PubMed ID: 9848573
[TBL] [Abstract][Full Text] [Related]
17. Effects of sucrose and mannitol on asparagine deamidation rates of model peptides in solution and in the solid state.
Li B; O'Meara MH; Lubach JW; Schowen RL; Topp EM; Munson EJ; Borchardt RT
J Pharm Sci; 2005 Aug; 94(8):1723-35. PubMed ID: 15986465
[TBL] [Abstract][Full Text] [Related]
18. Photolytic Labeling To Quantify Peptide-Water Interactions in Lyophilized Solids.
Chen Y; Topp EM
Mol Pharm; 2019 Mar; 16(3):1053-1064. PubMed ID: 30721080
[TBL] [Abstract][Full Text] [Related]
19. Kahalalides V-Y isolated from a Hawaiian collection of the sacoglossan mollusk Elysia rufescens.
Rao KV; Na MK; Cook JC; Peng J; Matsumoto R; Hamann MT
J Nat Prod; 2008 May; 71(5):772-8. PubMed ID: 18407693
[TBL] [Abstract][Full Text] [Related]
20. Pharmaceutical development of a parenteral formulation of the investigational anticancer drug clanfenur.
Jonkman-de Vries JD; Van den Bemt BJ; ten Bokkel-Huinink WW; Underberg WJ; Kettenes-van den Bosch JJ; Henrar RE; Bult A; Beijnen JH
PDA J Pharm Sci Technol; 1997; 51(2):89-95. PubMed ID: 9146040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
